Literature DB >> 32126288

Endocrine and immune effects of non-convulsive neurostimulation in depression: A systematic review.

Andrew J Perrin1, Carmine M Pariante2.   

Abstract

BACKGROUND: Non-convulsive neurostimulation is a rapidly-developing alternative to traditional treatment approaches in depression. Modalities such as repetitive Transcranial Magnetic Stimulation (rTMS), transcranial Direct Current Stimulation (tDCS), Vagal Nerve Stimulation (VNS) and Deep Brain Stimulation (DBS) are now recognized as potential treatments. How non-convulsive neurostimulation interventions impact the neurohormonal and neuroimmune changes that accompany depression remains relatively unknown. If this type of intervention can drive endocrine, immune, as well symptom changes in depression, non-convulsive neurostimulation may represent a viable, multi-faceted treatment approach in depression. We were therefore interested to understand the state of the literature in this developing area.
METHODS: A systematic review of all studies that examined the impact of non-convulsive neurostimulation interventions on the hypothalamic-pituitary-adrenal (HPA) axis and immune function in the form of cytokine production in depression.
RESULTS: We identified 15 human studies, 9 that examined rTMS, 2 that examined tDCS, 2 that examined VNS and 2 that examined electroacupuncture. 11 animal studies were also identified, 3 that examined rTMS, 2 that examined DBS and 6 that examined electroacupuncture. All types of non-convulsive neurostimulation were able to revert the increases in cortisol, ACTH and other components of the HPA axis that are seen in depressed patients, as well as to modulate the levels of key cytokines known to be up-regulated in depression, such as IL-1β, IL-6 and TNF-α. Changes in the HPA axis and levels of cytokines in response to non-convulsive neurostimulation often did not correlate with change in depressive symptoms. Most studies were not controlled trials and thus, significant methodologic variability existed. Furthermore, many human studies lacked a sham stimulation comparator arm. We were unable to conduct relevant meta-analyses due to the design heterogeneities, heterogeneity in the reported outcome measures and the limited number of studies retrieved. Animal studies generally supported the findings of those in human, but again, significant variability in methodology and study design were evident.
CONCLUSIONS: Non-convulsive neurostimulation interventions show promise in their ability to alter the endocrine and immune disturbances that accompany depression. Further research, which includes blinded, sham-controlled comparator designs is required.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokines; Depression; HPA axis; Inflammation; Neurostimulation; Treatment

Mesh:

Year:  2020        PMID: 32126288     DOI: 10.1016/j.bbi.2020.02.016

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  8 in total

Review 1.  Biomarkers for Deep Brain Stimulation in Animal Models of Depression.

Authors:  Jason Yuen; Aaron E Rusheen; Joshua Blair Price; Abhijeet S Barath; Hojin Shin; Abbas Z Kouzani; Michael Berk; Charles D Blaha; Kendall H Lee; Yoonbae Oh
Journal:  Neuromodulation       Date:  2022-02

2.  The efficacy of repetitive transcranial magnetic stimulation (rTMS) for young individuals with high-level perceived stress: study protocol for a randomized sham-controlled trial.

Authors:  Jingsong Wu; Mengyu Han; Youze He; Xiaoting Xie; Jian Song; Xiujuan Geng
Journal:  Trials       Date:  2021-05-25       Impact factor: 2.279

3.  Biogeography of the large intestinal mucosal and luminal microbiome in cynomolgus macaques with depressive-like behavior.

Authors:  Teng Teng; Gerard Clarke; Michael Maes; Yuanliang Jiang; Jun Wang; Xuemei Li; Bangmin Yin; Yajie Xiang; Li Fan; Xueer Liu; Jie Wang; Shouhuan Liu; Yunqing Huang; Julio Licinio; Xinyu Zhou; Peng Xie
Journal:  Mol Psychiatry       Date:  2021-11-01       Impact factor: 13.437

4.  Variation in Thyroid-Stimulating Hormone and Cognitive Disorders in Unmedicated Middle-Aged Patients with Major Depressive Disorder: A Proton Magnetic Resonance Spectroscopy Study.

Authors:  Hui Zhao; Shunkai Lai; Shuming Zhong; Yiliang Zhang; Hui Yang; Yanbin Jia
Journal:  Mediators Inflamm       Date:  2022-09-05       Impact factor: 4.529

5.  Combined repetitive transcranial magnetic stimulation and medication treatment for depression is associated with serum amyloid a level: Evidence from naturalistic clinical practice.

Authors:  You Xu; Li Han; Youdan Wei; Hongjing Mao; Zhenghe Yu
Journal:  Front Neurosci       Date:  2022-09-14       Impact factor: 5.152

6.  Fluoxetine treatment supports predictive validity of the three hit model of depression in male PACAP heterozygous mice and underpins the impact of early life adversity on therapeutic efficacy.

Authors:  Tamás Gaszner; József Farkas; Dániel Kun; Balázs Ujvári; Gergely Berta; Valér Csernus; Nóra Füredi; László Ákos Kovács; Hitoshi Hashimoto; Dóra Reglődi; Viktória Kormos; Balázs Gaszner
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-23       Impact factor: 6.055

Review 7.  Biomarkers for Deep Brain Stimulation in Animal Models of Depression.

Authors:  Jason Yuen; Aaron E Rusheen; Joshua Blair Price; Abhijeet S Barath; Hojin Shin; Abbas Z Kouzani; Michael Berk; Charles D Blaha; Kendall H Lee; Yoonbae Oh
Journal:  Neuromodulation       Date:  2021-06-09

8.  Improving Mental Health Services: A 50-Year Journey from Randomized Experiments to Artificial Intelligence and Precision Mental Health.

Authors:  Leonard Bickman
Journal:  Adm Policy Ment Health       Date:  2020-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.